智通财经网·2025-08-26 13:10Core Viewpoint - Fosun Pharma (02196) has announced a licensing agreement with Sitala for the development, production, and commercialization of FXS6837 and related products in regions outside of China, including Hong Kong, Macau, and Taiwan, which is expected to accelerate clinical development and expand the company's international product portfolio [1] Group 1 - The licensing agreement grants Fosun Pharma's subsidiary the rights to develop and commercialize FXS6837 globally, excluding China [1] - The agreement includes a provision for Fosun Pharma to acquire shares in Sitala valued at $5 million at no cost [1] - This collaboration aims to enhance the clinical development and commercialization process of licensed products on a global scale [1]